Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 3Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Solid Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Malignant Ascites 1Lung Neoplasms 1Glioma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

apatinib 2Drug Therapy 2Tretinoin 1Radiotherapy 1Pharmaceutical Services 1Nivolumab 1Methylprednisolone 1Ifosfamide 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Drug-Related Side Effects and Adverse Reactions × Nivolumab × Clear all
NCT05652673 2025-02-28

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Erasmus Medical Center

Phase NA Recruiting
80 enrolled
Dermatologic

Melanoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡